Sign in

CIK 0000730272 · Large accelerated filer

REPLIGEN CORP

Sign in to watch
Ticker
RGEN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
042729386
Phone
7814499560
Business address
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
  1. 4 Shares withheld for taxes CHIEF PRODUCT OFFICER gave up 334 shares (to pay taxes)
  2. 4 Planned sale Chief Executive Officer sold 3,832 shares at $140.00 ($536,480)
  3. 4 Grant or award Senior VP, R&D acquired 5,284 shares (grant or award)
  4. 4 Grant or award Chief Executive Officer acquired 24,134 shares (grant or award)
  5. 4 Grant or award Chief Operating Officer acquired 7,751 shares (grant or award)
  6. 4 Grant or award CFO acquired 7,751 shares (grant or award)
  7. 4 Shares withheld for taxes Chief Operating Officer gave up 62 shares (to pay taxes)
  8. 4 Shares withheld for taxes Senior VP, R&D gave up 42 shares (to pay taxes)
  9. 4 Shares withheld for taxes Chief Operating Officer gave up 3,911 shares (to pay taxes)
  10. 4 Shares withheld for taxes Chief Executive Officer gave up 1,954 shares (to pay taxes)
  11. 4 Shares withheld for taxes Director gave up 9,897 shares (to pay taxes)
  12. 4 Shares withheld for taxes CFO gave up 1,042 shares (to pay taxes)
  13. 4 Shares withheld for taxes Senior VP, R&D gave up 1,367 shares (to pay taxes)
  14. 4 Shares withheld for taxes CHIEF PRODUCT OFFICER gave up 221 shares (to pay taxes)
  15. 4 Grant or award CHIEF PRODUCT OFFICER acquired 2,288 shares (grant or award)
  16. 3 Insider Initial Statement of Ownership
  17. 4 Open-market sale Director sold 275 shares at $161.00 ($44,275)
  18. 4 Option exercise Director acquired 3,366 shares (option exercise)
  19. 4 Other disposition Director disposed of 2,000 shares (other)
  20. 4 Planned sale Chief Executive Officer sold 7,041 shares at $170.00 ($1,196,970)

Page 2 of 34 · 669 filings